This study further identified HSP90AA1, ESR1, AKT1, VCAM1, EGFR, CDK1, MAPK1, CDK2, MYC, HSPB1, and HSPA5 as the key targets of YZQX in the treatment of AD with comorbid depression. Here, MAPK1 is linked to depressive symptom measurement.